Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_1

25%

Ph not_applicable

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 1

Trials by Phase

Phase 11 (33.3%)

N/A2 (66.7%)

Trials by Status

terminated125%

completed250%

unknown125%

Recent Activity

0 active trials

Showing 4 of 4

completednot_applicable

Locus-coeruleus Function in Normal Elderly and AD Risk

NCT04403165

terminatedphase_1

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

NCT04933617

unknownnot_applicable

Study of Degenerescence CSF Hallmarks in Older Bipolar Patients

NCT02836054

completed

ADNI: Alzheimer's Disease Neuroimaging Initiative

NCT00106899

Clinical Trials (4)

Showing 4 of 4 trials

NCT04403165Not Applicable

Locus-coeruleus Function in Normal Elderly and AD Risk

Completed

NCT04933617Phase 1

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Terminated

NCT02836054Not Applicable

Study of Degenerescence CSF Hallmarks in Older Bipolar Patients

Unknown

NCT00106899

ADNI: Alzheimer's Disease Neuroimaging Initiative

Completed

All 4 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 4